Drugs in Dev. Infections and Infectious Diseases
IND Enabling
Israel 
Lead Product(s) : OMN6
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : EIC Accelerator
Deal Size : $13.0 million
Deal Type : Funding
Omnix Medical Wins €10.8M in EIC Accelerator Funding
Details : Funding secures the advancement of Omnix Medical’s lead compound OMN6 through Phase I and II clinical trials. OMN6 is a novel antimicrobial peptide for treating life-threatening infections caused by Gram-negative bacteria.
Product Name : OMN6
Product Type : Peptide
Upfront Cash : Undisclosed
January 25, 2021
Lead Product(s) : OMN6
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : EIC Accelerator
Deal Size : $13.0 million
Deal Type : Funding
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RHB-107 has demonstrated strong inhibition of SARS-CoV-2 viral replication in a human bronchial cell model and targets a host cell component involved in viral replication, minimizing potential for resistance due to viral mutations.
Product Name : RHB-107
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Upamostat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Opaganib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma
Details : Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S.
Product Name : Yeliva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2020
Lead Product(s) : Opaganib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
